# Study of BEBT-908 in Subjects With Advanced Hematological Tumors

> **NCT06082596** · PHASE1 · COMPLETED · sponsor: **BeBetter Med Inc** · enrollment: 32 (actual)

## Conditions studied

- Relapsed or Refractory Non-Hodgkin's Lymphoma
- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** BEBT-908 for injection

## Key facts

- **NCT ID:** NCT06082596
- **Lead sponsor:** BeBetter Med Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-02
- **Primary completion:** 2019-03-08
- **Final completion:** 2019-03-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06082596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06082596, "Study of BEBT-908 in Subjects With Advanced Hematological Tumors". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06082596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*